PHARMACODYNAMIC EFFECTS OF THE S2R MODULATOR CT1812 IN ALZHEIMER&#39;S DISEASE (AD) PATIENTS OBSERVED IN A META-ANALYSIS OF CSF PROTEOMES FROM SPARC AND SHINE PART A

Elayta (CT1812) - Cognition Therap

https://cslide.ctimeetingtech.com/global_storage/media/content/adpd23/ADPD23_-_Posters_for_website_Jan_30.pdf

Duc Duong 1; Lora Waybright 2; Kiran Pandey 3; Britney Lizama 2; Adam Mecca 4; Christopher Van Dyck 4; Michael Grundman 5; Kaj Blennow 6; Henrik Zetterberg 7; Anthony Caggiano 8; Nicholas Seyfried 9; Mary Hamby 2

Dec 23, 2022